Targeted and shielded adenovectors for cancer therapy View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2006-04-13

AUTHORS

Susan J. Hedley, Jian Chen, John D. Mountz, Jing Li, David T. Curiel, Nikolay Korokhov, Imre Kovesdi

ABSTRACT

Conditionally replicative adenovirus (CRAd) vectors are novel vectors with utility as virotherapy agents for alternative cancer therapies. These vectors have already established a broad safety record in humans and overcome some of the limitations of non-replicative adenovirus (Ad) vectors. In addition, one potential problem with these vectors, attainment of tumor or tissue selectivity has widely been addressed. However, two confounding problems limiting efficacy of these drug candidates remains. The paucity of the native Ad receptor on tumor tissues, and host humoral response due to pre-existing titers of neutralizing antibodies against the vector itself in humans have been highlighted in the clinical context. The well-characterized CRAd, AdΔ24-RGD, is infectivity enhanced, thus overcoming the lack of coxsackievirus and adenovirus receptor (CAR), and this agent is already rapidly progressing towards clinical translation. However, the perceived host humoral response potentially will limit gains seen from the infectivity enhancement and therefore a strategy to blunt immunity against the vector is required. On the basis of this caveat a novel strategy, termed shielding, has been developed in which the genetic modification of a virion capsid protein would provide uniformly shielded Ad vectors. The identification of the pIX capsid protein as an ideal locale for genetic incorporation of shielding ligands to conceal the Ad vector from pre-existing neutralizing antibodies is a major progression in the development of shielded CRAds. Preliminary data utilizing an Ad vector with HSV-TK fused to the pIX protein indicates that a shield against neutralizing antibodies can be achieved. The utility of various proteins as shielding molecules is currently being addressed. The creation of AdΔ24S-RGD, an infectivity enhanced and shielded Ad vector will provide the next step in the development of clinically and commercially feasible CRAds that can be dosed multiple times for maximum effectiveness in the fight against cancers in humans. More... »

PAGES

1412-1419

References to SciGraph publications

  • 1999-09-14. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration in GENE THERAPY
  • 2001-07-06. Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors in GENE THERAPY
  • 1995-03-01. Phage Libraries Displaying Cyclic Peptides with Different Ring Sizes: Ligand Specificities of the RGD-Directed Integrins in BIO/TECHNOLOGY
  • 1997-06. αv Integrins as receptors for tumor targeting by circulating ligands in NATURE BIOTECHNOLOGY
  • 2002-06-05. CAR- or αv integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice in GENE THERAPY
  • 2000-01-20. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo in ONCOGENE
  • 2002-11. AlbugraninTM, a Recombinant Human Granulocyte Colony Stimulating Factor (G-CSF) Genetically Fused to Recombinant Human Albumin Induces Prolonged Myelopoietic Effects in Mice and Monkeys in PHARMACEUTICAL RESEARCH
  • 2001-05. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity in GENE THERAPY
  • 2005-11-21. Oncolytic adenoviruses – selective retargeting to tumor cells in ONCOGENE
  • 2003-04-29. Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids in CANCER GENE THERAPY
  • 2000-07. Replicative adenoviruses for cancer therapy in NATURE BIOTECHNOLOGY
  • 2003. Adenovirus Retargeting and Systemic Delivery in HUMAN GENE THERAPY: CURRENT OPPORTUNITIES AND FUTURE TRENDS
  • 2001-03. Coxsackievirus–adenovirus receptor expression in ovarian cancer cell lines is associated with increased adenovirus transduction efficiency and transgene expression in CANCER GENE THERAPY
  • 2005-11-21. Development of transcriptionally regulated oncolytic adenoviruses in ONCOGENE
  • 2004-06-24. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus in GENE THERAPY
  • 2000-10. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy in NATURE MEDICINE
  • 2000-04-12. Effective repeat administration with adenovirus vectors to the muscle in GENE THERAPY
  • 2005-11-21. Oncolytic viral therapies – the clinical experience in ONCOGENE
  • 1998-07-10. Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro in GENE THERAPY
  • 2004-07. Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response in BULLETIN OF MATHEMATICAL BIOLOGY
  • 2003-10-06. Human adenovirus type 35: nucleotide sequence and vector development in GENE THERAPY
  • 2001-07. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions in NATURE MEDICINE
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s00262-006-0158-2

    DOI

    http://dx.doi.org/10.1007/s00262-006-0158-2

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1040647291

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/16612598


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Immunology", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adenoviridae", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Capsid", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Genetic Vectors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Models, Biological", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Oncolytic Virotherapy", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "VectorLogics, Inc., 35294, Birmingham, AL, USA", 
              "id": "http://www.grid.ac/institutes/grid.422131.7", 
              "name": [
                "VectorLogics, Inc., 35294, Birmingham, AL, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hedley", 
            "givenName": "Susan J.", 
            "id": "sg:person.01076645775.81", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01076645775.81"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Rheumatology, Department of Medicine, University of Alabama at Birmingham, 35294, Birmingham, AL, USA", 
              "id": "http://www.grid.ac/institutes/grid.265892.2", 
              "name": [
                "Division of Rheumatology, Department of Medicine, University of Alabama at Birmingham, 35294, Birmingham, AL, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Chen", 
            "givenName": "Jian", 
            "id": "sg:person.01144563407.49", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144563407.49"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Rheumatology, Department of Medicine, University of Alabama at Birmingham, 35294, Birmingham, AL, USA", 
              "id": "http://www.grid.ac/institutes/grid.265892.2", 
              "name": [
                "Division of Rheumatology, Department of Medicine, University of Alabama at Birmingham, 35294, Birmingham, AL, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Mountz", 
            "givenName": "John D.", 
            "id": "sg:person.07550405624.18", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07550405624.18"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Human Gene Therapy, Departments of Medicine, Pathology, and Surgery, and the Gene Therapy Center, University of Alabama at Birmingham, 35294, Birmingham, AL, USA", 
              "id": "http://www.grid.ac/institutes/grid.265892.2", 
              "name": [
                "Division of Human Gene Therapy, Departments of Medicine, Pathology, and Surgery, and the Gene Therapy Center, University of Alabama at Birmingham, 35294, Birmingham, AL, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Li", 
            "givenName": "Jing", 
            "id": "sg:person.014305542547.03", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014305542547.03"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Human Gene Therapy, Departments of Medicine, Pathology, and Surgery, and the Gene Therapy Center, University of Alabama at Birmingham, 35294, Birmingham, AL, USA", 
              "id": "http://www.grid.ac/institutes/grid.265892.2", 
              "name": [
                "Division of Human Gene Therapy, Departments of Medicine, Pathology, and Surgery, and the Gene Therapy Center, University of Alabama at Birmingham, 35294, Birmingham, AL, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Curiel", 
            "givenName": "David T.", 
            "id": "sg:person.014245610777.23", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014245610777.23"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "VectorLogics, Inc., 35294, Birmingham, AL, USA", 
              "id": "http://www.grid.ac/institutes/grid.422131.7", 
              "name": [
                "VectorLogics, Inc., 35294, Birmingham, AL, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Korokhov", 
            "givenName": "Nikolay", 
            "id": "sg:person.0707613760.08", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0707613760.08"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "VectorLogics, Inc., 35294, Birmingham, AL, USA", 
              "id": "http://www.grid.ac/institutes/grid.422131.7", 
              "name": [
                "VectorLogics, Inc., 35294, Birmingham, AL, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kovesdi", 
            "givenName": "Imre", 
            "id": "sg:person.014321624037.48", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014321624037.48"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/sj.gt.3302097", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050339567", 
              "https://doi.org/10.1038/sj.gt.3302097"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.gt.3301137", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016889019", 
              "https://doi.org/10.1038/sj.gt.3301137"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.cgt.7700578", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043243255", 
              "https://doi.org/10.1038/sj.cgt.7700578"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1209048", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008921180", 
              "https://doi.org/10.1038/sj.onc.1209048"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.gt.3302295", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047830311", 
              "https://doi.org/10.1038/sj.gt.3302295"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/77283", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020669485", 
              "https://doi.org/10.1038/77283"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/80474", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052662594", 
              "https://doi.org/10.1038/80474"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.gt.3301701", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004225872", 
              "https://doi.org/10.1038/sj.gt.3301701"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.cgt.7700284", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025334140", 
              "https://doi.org/10.1038/sj.cgt.7700284"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.gt.3300665", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014788738", 
              "https://doi.org/10.1038/sj.gt.3300665"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nbt0395-265", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027790898", 
              "https://doi.org/10.1038/nbt0395-265"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1209044", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005166945", 
              "https://doi.org/10.1038/sj.onc.1209044"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1203251", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008238922", 
              "https://doi.org/10.1038/sj.onc.1203251"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-3-662-05352-2_8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049747756", 
              "https://doi.org/10.1007/978-3-662-05352-2_8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1023/a:1020917732218", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021097700", 
              "https://doi.org/10.1023/a:1020917732218"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.gt.3301424", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024265520", 
              "https://doi.org/10.1038/sj.gt.3301424"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nbt0697-542", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006419246", 
              "https://doi.org/10.1038/nbt0697-542"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.gt.3301473", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009862085", 
              "https://doi.org/10.1038/sj.gt.3301473"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1209037", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025367553", 
              "https://doi.org/10.1038/sj.onc.1209037"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1016/j.bulm.2003.08.016", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040893485", 
              "https://doi.org/10.1016/j.bulm.2003.08.016"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.gt.3300995", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015936596", 
              "https://doi.org/10.1038/sj.gt.3300995"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/89901", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014409607", 
              "https://doi.org/10.1038/89901"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2006-04-13", 
        "datePublishedReg": "2006-04-13", 
        "description": "Conditionally replicative adenovirus (CRAd) vectors are novel vectors with utility as virotherapy agents for alternative cancer therapies. These vectors have already established a broad safety record in humans and overcome some of the limitations of non-replicative adenovirus (Ad) vectors. In addition, one potential problem with these vectors, attainment of tumor or tissue selectivity has widely been addressed. However, two confounding problems limiting efficacy of these drug candidates remains. The paucity of the native Ad receptor on tumor tissues, and host humoral response due to pre-existing titers of neutralizing antibodies against the vector itself in humans have been highlighted in the clinical context. The well-characterized CRAd, Ad\u039424-RGD, is infectivity enhanced, thus overcoming the lack of coxsackievirus and adenovirus receptor (CAR), and this agent is already rapidly progressing towards clinical translation. However, the perceived host humoral response potentially will limit gains seen from the infectivity enhancement and therefore a strategy to blunt immunity against the vector is required. On the basis of this caveat a novel strategy, termed shielding, has been developed in which the genetic modification of a virion capsid protein would provide uniformly shielded Ad vectors. The identification of the pIX capsid protein as an ideal locale for genetic incorporation of shielding ligands to conceal the Ad vector from pre-existing neutralizing antibodies is a major progression in the development of shielded CRAds. Preliminary data utilizing an Ad vector with HSV-TK fused to the pIX protein indicates that a shield against neutralizing antibodies can be achieved. The utility of various proteins as shielding molecules is currently being addressed. The creation of Ad\u039424S-RGD, an infectivity enhanced and shielded Ad vector will provide the next step in the development of clinically and commercially feasible CRAds that can be dosed multiple times for maximum effectiveness in the fight against cancers in humans.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s00262-006-0158-2", 
        "inLanguage": "en", 
        "isAccessibleForFree": false, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.7141772", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1096240", 
            "issn": [
              "0340-7004", 
              "1432-0851"
            ], 
            "name": "Cancer Immunology, Immunotherapy", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "11", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "55"
          }
        ], 
        "keywords": [
          "humoral response", 
          "pre-existing titers", 
          "Ad vectors", 
          "pre-existing neutralizing antibodies", 
          "adenovirus vector", 
          "host humoral response", 
          "cancer therapy", 
          "alternative cancer therapies", 
          "HSV-TK", 
          "replicative adenovirus vector", 
          "neutralizing antibodies", 
          "tumor tissue", 
          "tissue selectivity", 
          "Ad receptor", 
          "clinical context", 
          "virotherapy agents", 
          "infectivity enhancement", 
          "virion capsid proteins", 
          "major progression", 
          "capsid protein", 
          "antibodies", 
          "preliminary data", 
          "therapy", 
          "clinical translation", 
          "safety record", 
          "CRAd", 
          "adenovirus receptor", 
          "receptors", 
          "drug candidates", 
          "infectivity", 
          "humans", 
          "novel strategy", 
          "agents", 
          "tumors", 
          "cancer", 
          "titers", 
          "response", 
          "immunity", 
          "progression", 
          "protein", 
          "efficacy", 
          "coxsackievirus", 
          "adenovectors", 
          "tissue", 
          "paucity", 
          "utility", 
          "genetic modification", 
          "maximum effectiveness", 
          "novel vector", 
          "potential problems", 
          "PIX proteins", 
          "development", 
          "records", 
          "strategies", 
          "lack", 
          "next step", 
          "candidates", 
          "addition", 
          "data", 
          "identification", 
          "multiple times", 
          "caveats", 
          "effectiveness", 
          "fight", 
          "time", 
          "gain", 
          "vector", 
          "ligands", 
          "limitations", 
          "translation", 
          "incorporation", 
          "modification", 
          "molecules", 
          "enhancement", 
          "basis", 
          "ideal locale", 
          "problem", 
          "locales", 
          "selectivity", 
          "context", 
          "step", 
          "genetic incorporation", 
          "shielding", 
          "creation", 
          "shield", 
          "broad safety record", 
          "non-replicative adenovirus (Ad) vectors", 
          "native Ad receptor", 
          "Ad\u039424-RGD", 
          "lack of coxsackievirus", 
          "pIX capsid protein", 
          "Ad\u039424S-RGD", 
          "feasible CRAds"
        ], 
        "name": "Targeted and shielded adenovectors for cancer therapy", 
        "pagination": "1412-1419", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1040647291"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s00262-006-0158-2"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "16612598"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s00262-006-0158-2", 
          "https://app.dimensions.ai/details/publication/pub.1040647291"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2021-11-01T18:08", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_417.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s00262-006-0158-2"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00262-006-0158-2'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00262-006-0158-2'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00262-006-0158-2'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00262-006-0158-2'


     

    This table displays all metadata directly associated to this object as RDF triples.

    320 TRIPLES      22 PREDICATES      148 URIs      118 LITERALS      14 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s00262-006-0158-2 schema:about N18b963423c024a6a9b574c273a52168b
    2 N220713be30e644bc83ba83800edf424a
    3 N2cf496690d8c4b458f4146fa588c5ede
    4 N6b015f3eb4f7418489005937ee94e0a6
    5 N84acd5560aee4bb3a86d2035b90ff05f
    6 Nbead696ea5a640f7814b49ea5bf6c727
    7 Nff8a34c7c7744a2e837dbfdc26f7e219
    8 anzsrc-for:11
    9 anzsrc-for:1107
    10 schema:author N44d5aa2aef164ea188f68ebee0420b81
    11 schema:citation sg:pub.10.1007/978-3-662-05352-2_8
    12 sg:pub.10.1016/j.bulm.2003.08.016
    13 sg:pub.10.1023/a:1020917732218
    14 sg:pub.10.1038/77283
    15 sg:pub.10.1038/80474
    16 sg:pub.10.1038/89901
    17 sg:pub.10.1038/nbt0395-265
    18 sg:pub.10.1038/nbt0697-542
    19 sg:pub.10.1038/sj.cgt.7700284
    20 sg:pub.10.1038/sj.cgt.7700578
    21 sg:pub.10.1038/sj.gt.3300665
    22 sg:pub.10.1038/sj.gt.3300995
    23 sg:pub.10.1038/sj.gt.3301137
    24 sg:pub.10.1038/sj.gt.3301424
    25 sg:pub.10.1038/sj.gt.3301473
    26 sg:pub.10.1038/sj.gt.3301701
    27 sg:pub.10.1038/sj.gt.3302097
    28 sg:pub.10.1038/sj.gt.3302295
    29 sg:pub.10.1038/sj.onc.1203251
    30 sg:pub.10.1038/sj.onc.1209037
    31 sg:pub.10.1038/sj.onc.1209044
    32 sg:pub.10.1038/sj.onc.1209048
    33 schema:datePublished 2006-04-13
    34 schema:datePublishedReg 2006-04-13
    35 schema:description Conditionally replicative adenovirus (CRAd) vectors are novel vectors with utility as virotherapy agents for alternative cancer therapies. These vectors have already established a broad safety record in humans and overcome some of the limitations of non-replicative adenovirus (Ad) vectors. In addition, one potential problem with these vectors, attainment of tumor or tissue selectivity has widely been addressed. However, two confounding problems limiting efficacy of these drug candidates remains. The paucity of the native Ad receptor on tumor tissues, and host humoral response due to pre-existing titers of neutralizing antibodies against the vector itself in humans have been highlighted in the clinical context. The well-characterized CRAd, AdΔ24-RGD, is infectivity enhanced, thus overcoming the lack of coxsackievirus and adenovirus receptor (CAR), and this agent is already rapidly progressing towards clinical translation. However, the perceived host humoral response potentially will limit gains seen from the infectivity enhancement and therefore a strategy to blunt immunity against the vector is required. On the basis of this caveat a novel strategy, termed shielding, has been developed in which the genetic modification of a virion capsid protein would provide uniformly shielded Ad vectors. The identification of the pIX capsid protein as an ideal locale for genetic incorporation of shielding ligands to conceal the Ad vector from pre-existing neutralizing antibodies is a major progression in the development of shielded CRAds. Preliminary data utilizing an Ad vector with HSV-TK fused to the pIX protein indicates that a shield against neutralizing antibodies can be achieved. The utility of various proteins as shielding molecules is currently being addressed. The creation of AdΔ24S-RGD, an infectivity enhanced and shielded Ad vector will provide the next step in the development of clinically and commercially feasible CRAds that can be dosed multiple times for maximum effectiveness in the fight against cancers in humans.
    36 schema:genre article
    37 schema:inLanguage en
    38 schema:isAccessibleForFree false
    39 schema:isPartOf N9d872e42232a4a868bc28a801ff03d86
    40 Nec54eaec70564ee5996e614c401ecb79
    41 sg:journal.1096240
    42 schema:keywords Ad receptor
    43 Ad vectors
    44 AdΔ24-RGD
    45 AdΔ24S-RGD
    46 CRAd
    47 HSV-TK
    48 PIX proteins
    49 addition
    50 adenovectors
    51 adenovirus receptor
    52 adenovirus vector
    53 agents
    54 alternative cancer therapies
    55 antibodies
    56 basis
    57 broad safety record
    58 cancer
    59 cancer therapy
    60 candidates
    61 capsid protein
    62 caveats
    63 clinical context
    64 clinical translation
    65 context
    66 coxsackievirus
    67 creation
    68 data
    69 development
    70 drug candidates
    71 effectiveness
    72 efficacy
    73 enhancement
    74 feasible CRAds
    75 fight
    76 gain
    77 genetic incorporation
    78 genetic modification
    79 host humoral response
    80 humans
    81 humoral response
    82 ideal locale
    83 identification
    84 immunity
    85 incorporation
    86 infectivity
    87 infectivity enhancement
    88 lack
    89 lack of coxsackievirus
    90 ligands
    91 limitations
    92 locales
    93 major progression
    94 maximum effectiveness
    95 modification
    96 molecules
    97 multiple times
    98 native Ad receptor
    99 neutralizing antibodies
    100 next step
    101 non-replicative adenovirus (Ad) vectors
    102 novel strategy
    103 novel vector
    104 pIX capsid protein
    105 paucity
    106 potential problems
    107 pre-existing neutralizing antibodies
    108 pre-existing titers
    109 preliminary data
    110 problem
    111 progression
    112 protein
    113 receptors
    114 records
    115 replicative adenovirus vector
    116 response
    117 safety record
    118 selectivity
    119 shield
    120 shielding
    121 step
    122 strategies
    123 therapy
    124 time
    125 tissue
    126 tissue selectivity
    127 titers
    128 translation
    129 tumor tissue
    130 tumors
    131 utility
    132 vector
    133 virion capsid proteins
    134 virotherapy agents
    135 schema:name Targeted and shielded adenovectors for cancer therapy
    136 schema:pagination 1412-1419
    137 schema:productId N4bf311a749dd456f8f5b7c782d1791c0
    138 N976742c9718249348dd7ae437740ffe9
    139 Ne54864e78e07472e9b1768adceb250fb
    140 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040647291
    141 https://doi.org/10.1007/s00262-006-0158-2
    142 schema:sdDatePublished 2021-11-01T18:08
    143 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    144 schema:sdPublisher N6e9dc0ef467c4d2e9b10311d5d1679f2
    145 schema:url https://doi.org/10.1007/s00262-006-0158-2
    146 sgo:license sg:explorer/license/
    147 sgo:sdDataset articles
    148 rdf:type schema:ScholarlyArticle
    149 N044b2767880840e68cc7d63fda5fb50b rdf:first sg:person.01144563407.49
    150 rdf:rest Ne3f41d189261446a8fd967cfd5cdfad3
    151 N18b963423c024a6a9b574c273a52168b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    152 schema:name Oncolytic Virotherapy
    153 rdf:type schema:DefinedTerm
    154 N220713be30e644bc83ba83800edf424a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    155 schema:name Adenoviridae
    156 rdf:type schema:DefinedTerm
    157 N228645b6d2514ad583f564b5c94737fd rdf:first sg:person.014245610777.23
    158 rdf:rest N296489b3e2544c8480a611652ab2caf2
    159 N296489b3e2544c8480a611652ab2caf2 rdf:first sg:person.0707613760.08
    160 rdf:rest Nc0c9151853d746c5a82c3320bf9b6a48
    161 N2cf496690d8c4b458f4146fa588c5ede schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    162 schema:name Capsid
    163 rdf:type schema:DefinedTerm
    164 N44d5aa2aef164ea188f68ebee0420b81 rdf:first sg:person.01076645775.81
    165 rdf:rest N044b2767880840e68cc7d63fda5fb50b
    166 N4bf311a749dd456f8f5b7c782d1791c0 schema:name doi
    167 schema:value 10.1007/s00262-006-0158-2
    168 rdf:type schema:PropertyValue
    169 N6b015f3eb4f7418489005937ee94e0a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    170 schema:name Genetic Vectors
    171 rdf:type schema:DefinedTerm
    172 N6e9dc0ef467c4d2e9b10311d5d1679f2 schema:name Springer Nature - SN SciGraph project
    173 rdf:type schema:Organization
    174 N84acd5560aee4bb3a86d2035b90ff05f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    175 schema:name Neoplasms
    176 rdf:type schema:DefinedTerm
    177 N976742c9718249348dd7ae437740ffe9 schema:name dimensions_id
    178 schema:value pub.1040647291
    179 rdf:type schema:PropertyValue
    180 N9d872e42232a4a868bc28a801ff03d86 schema:issueNumber 11
    181 rdf:type schema:PublicationIssue
    182 Nbead696ea5a640f7814b49ea5bf6c727 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    183 schema:name Models, Biological
    184 rdf:type schema:DefinedTerm
    185 Nc0c9151853d746c5a82c3320bf9b6a48 rdf:first sg:person.014321624037.48
    186 rdf:rest rdf:nil
    187 Ncadfc52b991e4fa5859900eef73e313a rdf:first sg:person.014305542547.03
    188 rdf:rest N228645b6d2514ad583f564b5c94737fd
    189 Ne3f41d189261446a8fd967cfd5cdfad3 rdf:first sg:person.07550405624.18
    190 rdf:rest Ncadfc52b991e4fa5859900eef73e313a
    191 Ne54864e78e07472e9b1768adceb250fb schema:name pubmed_id
    192 schema:value 16612598
    193 rdf:type schema:PropertyValue
    194 Nec54eaec70564ee5996e614c401ecb79 schema:volumeNumber 55
    195 rdf:type schema:PublicationVolume
    196 Nff8a34c7c7744a2e837dbfdc26f7e219 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    197 schema:name Humans
    198 rdf:type schema:DefinedTerm
    199 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    200 schema:name Medical and Health Sciences
    201 rdf:type schema:DefinedTerm
    202 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
    203 schema:name Immunology
    204 rdf:type schema:DefinedTerm
    205 sg:grant.7141772 http://pending.schema.org/fundedItem sg:pub.10.1007/s00262-006-0158-2
    206 rdf:type schema:MonetaryGrant
    207 sg:journal.1096240 schema:issn 0340-7004
    208 1432-0851
    209 schema:name Cancer Immunology, Immunotherapy
    210 schema:publisher Springer Nature
    211 rdf:type schema:Periodical
    212 sg:person.01076645775.81 schema:affiliation grid-institutes:grid.422131.7
    213 schema:familyName Hedley
    214 schema:givenName Susan J.
    215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01076645775.81
    216 rdf:type schema:Person
    217 sg:person.01144563407.49 schema:affiliation grid-institutes:grid.265892.2
    218 schema:familyName Chen
    219 schema:givenName Jian
    220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01144563407.49
    221 rdf:type schema:Person
    222 sg:person.014245610777.23 schema:affiliation grid-institutes:grid.265892.2
    223 schema:familyName Curiel
    224 schema:givenName David T.
    225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014245610777.23
    226 rdf:type schema:Person
    227 sg:person.014305542547.03 schema:affiliation grid-institutes:grid.265892.2
    228 schema:familyName Li
    229 schema:givenName Jing
    230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014305542547.03
    231 rdf:type schema:Person
    232 sg:person.014321624037.48 schema:affiliation grid-institutes:grid.422131.7
    233 schema:familyName Kovesdi
    234 schema:givenName Imre
    235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014321624037.48
    236 rdf:type schema:Person
    237 sg:person.0707613760.08 schema:affiliation grid-institutes:grid.422131.7
    238 schema:familyName Korokhov
    239 schema:givenName Nikolay
    240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0707613760.08
    241 rdf:type schema:Person
    242 sg:person.07550405624.18 schema:affiliation grid-institutes:grid.265892.2
    243 schema:familyName Mountz
    244 schema:givenName John D.
    245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07550405624.18
    246 rdf:type schema:Person
    247 sg:pub.10.1007/978-3-662-05352-2_8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049747756
    248 https://doi.org/10.1007/978-3-662-05352-2_8
    249 rdf:type schema:CreativeWork
    250 sg:pub.10.1016/j.bulm.2003.08.016 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040893485
    251 https://doi.org/10.1016/j.bulm.2003.08.016
    252 rdf:type schema:CreativeWork
    253 sg:pub.10.1023/a:1020917732218 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021097700
    254 https://doi.org/10.1023/a:1020917732218
    255 rdf:type schema:CreativeWork
    256 sg:pub.10.1038/77283 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020669485
    257 https://doi.org/10.1038/77283
    258 rdf:type schema:CreativeWork
    259 sg:pub.10.1038/80474 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052662594
    260 https://doi.org/10.1038/80474
    261 rdf:type schema:CreativeWork
    262 sg:pub.10.1038/89901 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014409607
    263 https://doi.org/10.1038/89901
    264 rdf:type schema:CreativeWork
    265 sg:pub.10.1038/nbt0395-265 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027790898
    266 https://doi.org/10.1038/nbt0395-265
    267 rdf:type schema:CreativeWork
    268 sg:pub.10.1038/nbt0697-542 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006419246
    269 https://doi.org/10.1038/nbt0697-542
    270 rdf:type schema:CreativeWork
    271 sg:pub.10.1038/sj.cgt.7700284 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025334140
    272 https://doi.org/10.1038/sj.cgt.7700284
    273 rdf:type schema:CreativeWork
    274 sg:pub.10.1038/sj.cgt.7700578 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043243255
    275 https://doi.org/10.1038/sj.cgt.7700578
    276 rdf:type schema:CreativeWork
    277 sg:pub.10.1038/sj.gt.3300665 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014788738
    278 https://doi.org/10.1038/sj.gt.3300665
    279 rdf:type schema:CreativeWork
    280 sg:pub.10.1038/sj.gt.3300995 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015936596
    281 https://doi.org/10.1038/sj.gt.3300995
    282 rdf:type schema:CreativeWork
    283 sg:pub.10.1038/sj.gt.3301137 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016889019
    284 https://doi.org/10.1038/sj.gt.3301137
    285 rdf:type schema:CreativeWork
    286 sg:pub.10.1038/sj.gt.3301424 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024265520
    287 https://doi.org/10.1038/sj.gt.3301424
    288 rdf:type schema:CreativeWork
    289 sg:pub.10.1038/sj.gt.3301473 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009862085
    290 https://doi.org/10.1038/sj.gt.3301473
    291 rdf:type schema:CreativeWork
    292 sg:pub.10.1038/sj.gt.3301701 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004225872
    293 https://doi.org/10.1038/sj.gt.3301701
    294 rdf:type schema:CreativeWork
    295 sg:pub.10.1038/sj.gt.3302097 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050339567
    296 https://doi.org/10.1038/sj.gt.3302097
    297 rdf:type schema:CreativeWork
    298 sg:pub.10.1038/sj.gt.3302295 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047830311
    299 https://doi.org/10.1038/sj.gt.3302295
    300 rdf:type schema:CreativeWork
    301 sg:pub.10.1038/sj.onc.1203251 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008238922
    302 https://doi.org/10.1038/sj.onc.1203251
    303 rdf:type schema:CreativeWork
    304 sg:pub.10.1038/sj.onc.1209037 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025367553
    305 https://doi.org/10.1038/sj.onc.1209037
    306 rdf:type schema:CreativeWork
    307 sg:pub.10.1038/sj.onc.1209044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005166945
    308 https://doi.org/10.1038/sj.onc.1209044
    309 rdf:type schema:CreativeWork
    310 sg:pub.10.1038/sj.onc.1209048 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008921180
    311 https://doi.org/10.1038/sj.onc.1209048
    312 rdf:type schema:CreativeWork
    313 grid-institutes:grid.265892.2 schema:alternateName Division of Human Gene Therapy, Departments of Medicine, Pathology, and Surgery, and the Gene Therapy Center, University of Alabama at Birmingham, 35294, Birmingham, AL, USA
    314 Division of Rheumatology, Department of Medicine, University of Alabama at Birmingham, 35294, Birmingham, AL, USA
    315 schema:name Division of Human Gene Therapy, Departments of Medicine, Pathology, and Surgery, and the Gene Therapy Center, University of Alabama at Birmingham, 35294, Birmingham, AL, USA
    316 Division of Rheumatology, Department of Medicine, University of Alabama at Birmingham, 35294, Birmingham, AL, USA
    317 rdf:type schema:Organization
    318 grid-institutes:grid.422131.7 schema:alternateName VectorLogics, Inc., 35294, Birmingham, AL, USA
    319 schema:name VectorLogics, Inc., 35294, Birmingham, AL, USA
    320 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...